• Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
  • March 20, 2020
  • Author: EURETINA Brief

Early clinical results report gene therapy treatment for X-linked retinitis pigmentosa caused by mutations in RPGR

Research from the University of Oxford has reported early results from the first-in-human Phase 1/2, dose-escalation clinical trial for X-linked RP caused by mutations in the RP GTPase regulator (RPGR) gene. 18 patients had 6-month follow up data focused on safety outcomes with additional secondary outcomes with preliminary results from visual acuity, microperimetry and central retinal thickness. The patients were treated with increasing doses of a viral vector carrying an RPGR gene (RP GTPase regulator (RPGR)) in which the DNA had been altered, but in a manner that still allowed correct production of the missing protein.

 

X-linked retinitis pigmentosa (XLRP) is an incurable genetic disease that causes blindness in males and affects approximately one in 15,000 people. The disease is caused by a defect in the RPGR gene which is located on the X-chromosome.  Mutations in the RPGR gene can be associated with a rod-cone or cone-rod dystrophy phenotype. The most common presentation is as a rod-cone dystrophy. It is one of the most severe forms of RP with nyctalopia in most affected males before 10 years of age and progression to legal blindness by the third to fourth decade. The disorder is initially identified with difficulties in scotopic visual function, where there is a predominant loss of rod photoreceptors. Simultaneously, peripheral vision deteriorates, resulting in visual field constriction on perimetry findings. The majority of cases present with a rod-cone dystrophy-type disease progression, where central visual acuity is initially less impaired than the peripheral field loss. The fovea is ultimately affected in all cases during the late stages of the disease by subsequent cone photoreceptor degeneration.

 

In the study, 18 patients with genetically confirmed variants in RPGR were recruited into 6 cohorts of 3 patients, each receiving increasing concentrations from 5 × 10^10 genomic particles (gp) ml−1 to 5 × 10^12 gp ml−1, using AAV8-coRPGR via a subretinal injection.  In follow up to six-month data, the researchers suggested that the vector did not have any dose-limiting toxicities, while the secondary outcomes provided visual acuity, microperimetry and central retina thickness results.  BCVA (ETRS letters) showed treated eyes (n = 18) with a baseline mean of 57.2 letters, compared to a mean of 57.1 at 6 months, i.e., a change at 6 months of −0.1 letters (95% CI −2.8 to 2.6). Untreated eyes (n = 18) had a baseline mean of 65.9 letters, compared to a mean of 66.7 letters at 6 months, i.e., at 6 months +0.8 letters (95% CI −1.3 to 2.9). Mean microperimetry had a baseline mean of 3.2 dB compared with a mean of 3.6 dB at 6 months, i.e., a + 0.4 dB change (95% CI −0.7 to 1.7). And finally, in terms of central retinal thickness assessment, there was a baseline mean of 143.6μm, compared to a mean of 132.7μm at 6 months, i.e., a mean change of −10.8μm (95% CI −25.1 to 3.5).  In essence, it will be at least 12, 24 and 36 months later before a clearer picture can adjudicate on how the technology might work.

PrevPrevious
NextNext

You might also like

EURETINA Hamburg 2022 Keynote Speakers

Read More

EURETINA Educational Webinar: Diabetes and Vascular Diseases (23 Jun, 2022)

Read More

Apellis International: The Future of Geographic Atrophy: advancing diagnosis, treatment and management

Read More

Meet the Keynote Speakers

Keynote Speaker - Sobha Sivaprasad
Euretina Lecture with Sobha Sivaprasad
Opthalmologica Lecture with Enrico Borrelli
Ophthalmologica Lecture with Enrico Borrelli
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Kreissig Award Lecture with Hiroko Terasaki
Kreissig Award Lecture with Hiroko Terasaki

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2022 Hamburg

Opportunities

Memberships

Forum

About

Privacy Policy

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2021 All rights reserved
  • Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login